Advertisement

Article

Treatment Considerations for Photobiomodulation for Retinal Disease

Careful patient evaluation will help identify best candidates.

By: Mohammad Bagher Rajabi, MD, Gunjan Awatramani, Alan Sherif, Gunay Uludag Kirimli, MD, Ingrid U. Scott, MD, MPH, Diana V. Do, MD
Ophthalmology Management August 24, 2026
3 Topic Commentaries

Treatment Considerations for Photobiomodulation for Retinal Disease

  • Malvina Eydelman, MD

    Ophthalmology; Medical devices regulation

    •

    U.S. Food and Drug Administration

    Today’s action brings to market the first therapeutic option for adult patients with dry AMD,

    Source
  • Diana V. Do, MD

    Retina/Vitreoretinal diseases

    •

    Byers Eye Institute, Stanford University School of Medicine

    We found that PBM provided a sustained and improved best corrected visual acuity—a very exciting step towards therapy for patients everywhere.

    Source
  • Srinivas R. Sadda, MD

    Retina/AMD

    •

    Doheny Eye Institute; David Geffen School of Medicine, University of California, Los Angeles

    This authorization was associated with the results of the LIGHTSITE III randomized clinical trial,

    Source